ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 16 of 55
Up
JMBS 2022, 7(5): 107–113
https://doi.org/10.26693/jmbs07.05.107
Clinical Medicine

Urinary Melatonin Metabolite in Premature Infants with Extremely and Very Low Birth Weight

Kuzienkova Ganna A., Klymenko Tetyana M.
Abstract

The aim. Determination of daily urinary 6-sulfatoxymelatonin in premature infants with extremely and very low birth weight. Materials and methods. A non-invasive, descriptive, single-centered study involving data of 96 premature infants with weight less than 1500 g : 46 infants with extremely and 50 infants with very low birth weight. The study included a detailed scrutiny of history and objective examinations, data from medical records, anthropometric measurements, and daily urine collection. Determination of 6 - SM in the 24-hours urine collection from premature infants was performed by enzyme immunoassay on the analyzer “Labline-90” (Austria) using a commercial test system manufactured by “LDR” (LABOR DIAGNOSTIKA NORD GmbH & Co.KG, Germany) according to the provided instruction. 166 portions of urine were collected during the examination in time intervals: 96 portions of urine in premature infants at 1st day of life and 70 portions at 10th – 14th day of life. Results. Ante- and intranatal periods for the infants enrolled in the study were characterized by conditions: premature rupture of membranes 37 (38.5%), multiple pregnancy 16 (16.6%), preeclampsia 15 (15.6%), isthmic-cervical insufficiency 11 (11.5%), placental abruption 8 (8.3%), extra corporal fertilization 5 (5.2%), chorioamnionitis 4 (4.2%); caesarean section urgent 33 (34.4%) and planned 24 (25.0%). There was no any significant difference in frequency of ante – and intranatal pathology between ELBW and VLBW. Antenatal administration of corticosteroids for reduce the severity of neonatal respiratory distress syndrome occurred in all mothers of infants enrolled in the study. There was significant low urinary 6-sulfatoxymelatonin level in extremely low birth weight infants (median 120.0 pg /mL) on the 1st day of life compared with very low birth weight (median 348.5 pg / mL). There was no difference at 10 – 14th days. The predictive level of lethal outcome in infants with extremely low birth weight is ≤ 84 pg / mL with sensitivity 84.62% and specificity 70.0%. Conclusion. In infants with extremely and very low birth weight the determining the urinary 6-sulfatoxymelatonin is a non-invasive method. The significant decrease level of urinary 6-sulfatoxymelatonin in infants with extremely low birth weight on the first day of life was found. The measurement of urinary 6-sulfatoxymelatonin will allow to establish the prediction of perinatal outcomes. Its levels <87 pg / mL is associated with lethal outcomes. Authors speculate than it will the way for future supplement of melatonin to premature infants and study of its effect on perinatal outcomes

Keywords: premature infants, melatonin, urinary 6-sulfatoxymelatonin

Full text: PDF (Eng) 288K

References
  1. Rezzani R, Franco C, Hardeland R, Rodella LF. Thymus-Pineal Gland Axis: Revisiting Its Role in Human Life and Ageing. Int J Mol Sci. 2020 Nov 20;21(22):8806. PMID: 33233845. PMCID: PMC7699871. https://doi.org/10.3390/ijms21228806
  2. Cipolla-Neto J, Amaral FGD. Melatonin as a Hormone: New Physiological and Clinical Insights. Endocr Rev. 2018;39:990-1028. PMID: 30215696. https://doi.org/10.1210/er.2018-00084
  3. Boga JA, Caballero B, Potes Y, Perez-Martinez Z, Reiter RJ, Vega-Naredo I, et al. Therapeutic potential of melatonin related to its role as an autophagy regulator: A review. J Pineal Res. 2019;66:e12534. PMID: 30329173. https://doi.org/10.1111/jpi.12534
  4. Hardeland R. Antioxidative protection by melatonin: Multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005;27:119-130. https://doi.org/10.1385/ENDO:27:2:119
  5. Hurley T, O'Dea M, Aslam S, Aly H, Robertson N, Molloy E. Melatonin treatment for newborns with hypoxic ischaemic encephalopathy. Cochrane database of systematic reviews. 2020 Oct. https://doi.org/10.1002/14651858.CD013754
  6. Xu J, Huang L, Sun GP. Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis. Sci Rep. 2017 Jul 13;7(1):5353. PMID: 28706222. PMCID: PMC5509698. https://doi.org/10.1038/s41598-017-05752-9
  7. Biran V, Decobert F, Bednarek N, Boizeau P, Benoist JF, Claustrat B, et al. Baud O. Melatonin Levels in Preterm and Term Infants and Their Mothers. Int J Mol Sci. 2019 Apr 27;20(9):2077. PMID: 31035572. PMCID: PMC6540351. https://doi.org/10.3390/ijms20092077
  8. Manuck TA, Rice MM, Bailit JL, Grobman WA, Reddy UM, Wapner RJ, et al. Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort. Am J Obstet Gynecol. 2016 Jul;215(1):103.e1-103.e14. PMID: 26772790. PMCID: PMC4921282. https://doi.org/10.1016/j.ajog.2016.01.004
  9. Executive summary: Neonatal encephalopathy and neurologic outcome, second edition. Report of the American College of Obstetricians and Gynecologists' Task Force on Neonatal Encephalopathy. Obstet Gynecol. 2014 Apr;123(4):896-901. PMID: 24785633. https://doi.org/10.1097/01.AOG.0000445580.65983.d2
  10. Volpe JJ. Neonatal encephalopathy: an inadequate term for hypoxic-ischemic encephalopathy. Ann Neurol. 2012;72:156-166. PMID: 22926849. https://doi.org/10.1002/ana.23647
  11. Herrera TI, Edwards L, Malcolm WF, Smith PB, Fisher KA, Pizoli C, et al. Outcomes of preterm infants treated with hypothermia for hypoxic-ischemic encephalopathy. Early Hum Dev. 2018 Oct;125:1-7. PMID: 30144709. https://doi.org/10.1016/j.earlhumdev.2018.08.003
  12. Burgess HJ, Park M, Wyatt JK, Fogg LF. Home dim light melatonin onsets with measures of compliance in delayed sleep phase disorder. J Sleep Res. 2016; Jun;25(3):314-7. PMID: 26847016. https://doi.org/10.1111/jsr.12384
  13. Chen BH, Park JH, Lee YL, Kang IJ, Kim DW, Hwang IK, et al. Melatonin improves vascular cognitive impairment induced by ischemic stroke by remyelination via activation of ERK1/2 signaling and restoration of glutamatergic synapses in the gerbil hippocampus. Biomed Pharmacother. 2018;108:687-697. PMID: 30245469. https://doi.org/10.1016/j.biopha.2018.09.077
  14. Benloucif S, Burgess HJ, Klerman EB, Lewy AJ, Middleton B, Murphy PJ, et al. Measuring melatonin in humans. J Clin Sleep Med. 2008; Feb 15;4(1):66-9. PMID: 18350967. PMCID: PMC2276833. https://doi.org/10.5664/jcsm.27083
  15. Kennaway DJ, Stamp GE, Goble FC. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab. 1992 Aug;75(2):367-9. PMID: 1639937. https://doi.org/10.1210/jcem.75.2.1639937
  16. Sivan Y, Laudon M, Tauman R, Zisapel N. Melatonin production in healthy infants: evidence for seasonal variations. Pediatr Res. 2001 Jan;49(1):63-8. PMID: 11134493. https://doi.org/10.1203/00006450-200101000-00015
  17. Marseglia L, Gitto E, Laschi E, Giordano M, Romeo C, Cannavò L, et al. Antioxidant Effect of Melatonin in Preterm Newborns. Oxid Med Cell Longev. 2021 Nov 19;2021:6308255. PMID: 34840669. PMCID: PMC8626170. https://doi.org/10.1155/2021/6308255
  18. Perrone S, Santacroce A, Longini M, Proietti F, Bazzini F, Buonocore G. The free radical diseases of prematurity: from cellular mechanisms to bedside. Oxid Med Cell Longev. 2018 Jul 24;2018:7483062. PMID: 30140369. PMCID: PMC6081521. https://doi.org/10.1155/2018/7483062.7483062
  19. Tauman R, Zisapel N, Laudon M, Nehama H, Sivan Y. Melatonin production in infants. Pediatr Neurol. 2002 May;26(5):379-82. PMID: 12057799. https://doi.org/10.1016/s0887-8994(01)00417-9
  20. Teng RJ. Oxidative Stress in Neonatal Lung Diseases. In: Chakraborti S, Chakraborti T, Das S, Chattopadhyay D, Eds. Oxidative Stress in Lung Diseases. Singapore: Springer; 2019. PMCID: PMC6659274. https://doi.org/10.1007/978-981-13-8413-4_3
  21. Perrone S, Tataranno ML, Buonocore G. Oxidative stress and bronchopulmonary dysplasia. J Clin Neonatol. 2012;1:109-114. PMID: 24027702. PMCID: PMC3762019. https://doi.org/10.4103/2249-4847.101683
  22. D'Angelo G, Chimenz R, Reiter RJ, Gitto E. Use of Melatonin in Oxidative Stress Related Neonatal Diseases. Antioxidants (Basel). 2020;9(6):477. PMID: 32498356. PMCID: PMC7346173. https://doi.org/10.3390/antiox9060477
  23. Garofoli F, Longo S, Pisoni C, Accorsi P, Angelini M, Aversa S, et al. Oral melatonin as a new tool for neuroprotection in preterm newborns: study protocol for a randomized controlled trial. Trials. 2021 Jan 22(1):82. PMID: 33482894 PMCID: PMC7820522. https://doi.org/10.1186/s13063-021-05034-w
  24. Korver AM, Admiraal RJ, Kant SG, Dekker FW, Wever CC, Kunst HP, et al. Causes of permanent childhood hearing impairment. Laryngoscope. 2011 Feb;121(2):409-16. PMID: 21271598. https://doi.org/10.1002/lary.21377
  25. Joint Committee on Infant Hearing, American Academy of Audiology, American Academy of Pediatrics American Speech-Language-Hearing Association; Directors of Speech and Hearing Programs in State Health and Welfare Agencies. Year 2000 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs. Pediatrics. 2000;106(4):798-817. PMID: 11015525. https://doi.org/10.1542/peds.106.4.798